biotech · Ataxia Telangiectasia · Ataxia Telangiectasia (A-T) · QNCX
Quince Therapeutics
Quince Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker QNCX. Primary therapeutic focus areas include Ataxia Telangiectasia, Ataxia Telangiectasia (A-T), Ul
South San Francisco, USA HQ
2012 Founded
21 Employees
Public company Type
QNCX · NYSE Ticker
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2012
- Employees
- 21
- Programs
- 10
- Drugs
- 8
- Patents
- 1
Dexamethasone sodium phosphate for encapsulation into autoerythrocytes
Phase 3 · small molecule · Ataxia Telangiectasia (A-T)
Dexamethasone sodium phosphate for encapsulation into autoerythrocytes for Ataxia Telangiectasia (A-T) is a Phase 3 program (small_molecule) at Quince Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code IEDAT-05-2024
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Quince Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Ataxia Telangiectasia (A-T)
- Status
- active
- Trials
- 1